RxDoctor Payments Data

Kiet Ma, DO

Pulmonary Disease · Erie, PANPI 1497098776

Payments from drug & device makers

$7,437in general payments, 2019–2025

Across 32 payments — averaging $232.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Veran Medical Technologies, Inc.$1K
  • Boehringer Ingelheim$357
  • AstraZeneca$164
  • Regeneron Healthcare Solutions, Inc.$140
  • Insmed, Inc.$139
  • plus $344 from 4 others

What the payments were for

  • Travel & lodging$2,66036%
  • Food & beverage$1,53121%
  • Education$3,24644%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,437 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,004
Medicare patients
248
Services billed
814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter109$88,953
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr111$59,264
Breo ElliptaFluticasone/Vilanterol47$26,045
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$19,614
Spiriva RespimatTiotropium Bromide18$16,087
Incruse ElliptaUmeclidinium Bromide34$12,193
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,184
Advair HfaFluticasone Propion/Salmeterol12$5,586
Albuterol Sulfate HfaAlbuterol Sulfate87$2,143
Ventolin HfaAlbuterol Sulfate11$1,035
Fluticasone Propionate22$292
Prednisone30$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$108$186,454301 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$357$35,70252 claims
AstraZenecaBreztri Aerosphere$164$6,18411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →